Remedium Lifecare Ltd. (formerly known as Roxy Exports Limited) has unveiled a significant milestone in its growth journey with the announcement of its ₹49.19 crore Rights Issue. The company, listed on the Bombay Stock Exchange (BSE), is gearing up for an exciting opportunity for investors to enhance their stakes in the company.

The Rights Issue opens on April 30, 2025, and will close on May 14, 2025. The issue price is set at ₹1 per share, a potentially attractive opportunity given the closing price of ₹1.79 as on April 25, 2025. The rights issue ratio is 61 Rights Equity Shares for every 50 Equity Shares held on the Record Date of April 15, 2025.

This capital-raising initiative is designed to strengthen the company’s working capital, invest in cutting-edge R&D, and scale up production of high-value pharmaceutical intermediates. Additionally, the proceeds will support global market expansion, with a focus on Europe and Asia.

The funds will also be utilized for the establishment of advanced research laboratories specializing in high-demand therapeutic areas such as Central Nervous System (CNS) disorders, oncology, and metabolic conditions. These segments are crucial in global healthcare, and Remedium Lifecare is positioning itself to contribute significantly to addressing these health challenges.

In a press statement, Mr. Adarsh Munjal, Managing Director of Remedium Lifecare Ltd., emphasized the significance of the rights issue in advancing the company’s strategic vision. He stated, “This Rights Issue represents a significant milestone in our journey to becoming a globally recognized, innovation-led pharmaceutical company.” He further noted that the funds would help strengthen the company's strategic partnerships, particularly in Europe and Asia.

The proceeds from this initiative will not only help accelerate Remedium’s R&D and production capabilities but will also bolster its financial resilience by contributing to the prepayment of debts.

Remedium Lifecare’s growth strategy is robust, with a strong focus on quality, compliance, and a global reach. The company is a prominent player in India’s pharmaceutical ecosystem, providing critical supply chain management for the pharmaceutical industry. This rights issue offers an attractive opportunity for investors to become part of an expanding company with a focus on long-term value and growth in India’s booming pharmaceutical sector.

As India continues to grow as a reliable pharmaceutical manufacturing and supply chain hub, Remedium Lifecare’s contributions align with the nation’s Make in India initiative, fostering job creation and sectoral growth.

The Upcoming IPOs in this week and coming weeks are Arunaya Organics,Kenrik Industries,Wagons Learning,Srigee DLM.

The Current active IPO are Ather Energy, Iware Supplychain Services.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.